IL6 and fatty liver disease: All groups receiving silymarin showed a decrease in liver malondialdehyde content, expression of fatty acid synthase, tumour necrosis factor alpha, interleukin 6 (IL‐6) genes in the liver, and hepatic steatosis than the control, except those fed the PSM100 diet.